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Abstract
The need for tissue engineered bone to treat complex craniofacial bone defects secondary to
congenital anomalies, trauma, and cancer extirpation is sizeable. Traditional strategies for
treatment have focused on autologous bone in younger patients and bone substitutes in older
patients. However, the capacity for merging new technologies, including the creation of nano and
microfiber scaffolds with advances in natal sources of stem cells, is crucial to improving our
treatment options. The advantages of using smaller diameter fibers for scaffolding are two-fold:
the similar fiber diameters mimic the in vivo extracellular matrix construct;, and smaller fibers also
provide a dramatically increased surface area for cell-scaffold interactions. In this study, we
compare the capacity for a polymer with Federal Drug Administration (FDA) approval for use in
humans, poly-co-glycolytic acid (PLGA) from Delta polymer, to support osteoinduction of
mesenchymal stem cells (MSCs) harvested from the umbilical cord (UC) and palate periosteum
(PP). Proliferation of both UC- and PP-derived MSCs was improved on PLGA scaffolds. PLGA
scaffolds promoted UC MSC differentiation (indicated by earlier gene expression and higher
calcium deposition), but not in PP-derived MSCs. UC-derived MSCs on PLGA nano-micro-fiber
scaffolds have potential clinical utility in providing solutions for craniofacial bone defects, with
the added benefit of earlier availability.
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Introduction
Craniofacial bone defects are a significant cause of infant morbidity, with significant
lifetime functional, esthetic, and social consequences.(1, 2) Effective repair of these defects
represents a challenging problem, requiring extensive surgical procedures, generally staged
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from infancy through adulthood. The most common treatment for craniofacial defects is
autologous bone grafting. Complications for autografts are as high as 30% and include
donor site morbidity, pain, infection, and hematoma; an ever-present concern is limited
availability of donor material.(3–5) Tissue engineering constitutes a promising approach to
overcome current treatment limitations.(6–8) Primary requirements for bone engineering
include a biocompatible and biodegradable scaffold to provide temporary mechanical
support, an autologous cell source that is readily and reliably available with the capacity to
fill the defect.
High surface area nano-micro-fibers (NMF) (9) can be created from multiple natural and
synthetic materials,(10–12) providing 3-dimensional scaffolds that mimic the extracellular
matrix (ECM) and promote cellular adherence, proliferation and migration.(13, 14) The ECM
has fibers with a wide range of diameters, and include collagens (generally 10–500 nm) and
elastin fibrils (100–200 nm) depending on tissue structure, location, and age. In most tissues,
collagen fibrils are packed in wider fibers with diameters 1–20 μm. Elastic fibrils are usually
found packed in wider fiber networks with diameters of 0.2–1.5 μm.(15) Because of this
variety in fiber sizes, NMF with variations in size will most closely mimic the ECM.
NMF can be created using several techniques, the most common of which is electrospinning
(Figure 1).(10) Though the polymers available for electrospinning are numerous, the use of
materials with proven implantation histories would be valuable. Individual polymers used in
resorbable plating systems have been used to create nanofibers, and include poly-L-lactic
acid (PLA), and poly-lactic-co-glycolytic acid (PLGA);(11)(16) however, there are no reports
in the literature of any patented resorbable plating systems used for NMF creation. In this
study, we use the Delta System™ from Stryker® (Kalamazoo, Michigan, USA) to
electrospin NMF.
There are multiple possibilities for mesenchymal stem cell (MSC) sources in pediatric
patients, one of which, the umbilical cord (UC), has been significantly underutilized to date.
The UC is discarded, and may represent the largest untapped source of embryonic-like
MSCs.(17, 18) Another theoretical source of stem cells would be any routinely encountered
tissue at the time of a surgical procedure. In adults, lipoaspirate and abdominoplasty
specimens with fat have been utilized in this manner.(19)However, in children, there are no
surgical procedures that routinely discard large quantities of fat. There are however, other
procedures, where the periosteal layer (a rich site of MSCs) are routinely exposed,(20–22)
including cleft lip repair (3 months-of-age), cranial vault reconstruction (6 months-of-age)
or palate repair (9 to 12 months-of-age). The periosteal layer is known to promote bone
healing, as well as prevent desiccation and infection of underlying bone, in part because of
the multi-potential MSCs. These MSCs may not have the embryonic-like characteristics of
UC MSCs,(23) but could have significant value in tissue engineered bone for children.(22)
We have previously demonstrated that UC MSCs appear to have a higher capacity for
osteoinduction than PP MSCs. A potential explanation for this is that UC MSCs may be
more primitive and hence more plastic, resulting in increased osteoinduction potential.(23)
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In this study we report the capacity of poly (lactic-co-glycolic acid) (PLGA; Delta System™
polymer resorbable craniofacial plates and screws) to support osteoinduction of MSCs
harvested from two different sources, the human umbilical cord and palate periosteum.
Materials and Methods
Electrospinning Nano-micro-fibers
To generate NMF scaffolds, Delta System™ resorbable implants (PLGA) from Stryker®
(Kalamazoo, Michigan, USA) were solubilized in 3:1v/v dichloromethane:dimethyl
formamide at 8% wt/v concentration, and electrospun at 4.4 kV/inch, CO2 flow rate of 1 l/
min, and polymer flow rate of 0.1 ml/hr (Figure 1). NMF were visualized by scanning
electron microscopy (SEM) to determine fiber uniformity (Figure 2). Fibers were sterilized
in 70% ethanol under the UV lamp for 4 hours, and incubated with media overnight to
facilitate cell attachment.
NF diameter and pore size distribution
Fiber images were obtained on a Hitachi S-3200N environmental SEM. To determine fiber
diameter distribution, the ASTM D 629 and AATCC Test Method 20A for fiber counting in
microscopic analysis was adapted from industry standard methods. Briefly, 4–5 SEM
images were taken randomly from each sample with a magnification range (1000–2000X).
Fiber diameters were measured in each image starting at the center of the image’s left edge
and moving in the horizontal direction to the center of the right edge. Fiber diameters were
measured by moving vertically from the top edge center to the bottom edge center of the
image. The fiber diameter measurements from all the images (4–5 per sample) were then
combined for analysis. A total of 150–200 fibers were analyzed for each of the samples.
Pore size distributions were measured with quasi-2D layers of fibers only 2 to 4 fiber
diameters thick. SEMs were obtained with sufficient contrast to allow further image
manipulations. SEM images of these layers were converted to black-and-white images with
appropriate thresholds. Pore size region recognition and area measurements were performed
on the converted images using ImageJ software.(24)
Umbilical Cord MSC Harvest
Following Institutional Review Board approval, UC MSCs were harvested using an explant
technique, as previously described.(23) Briefly, UC were obtained following appropriate
consent (IRB: 06-0801), the blood vessels were discarded, and the remaining Wharton’s
Jelly and surrounding tissue were cut into small explants and cultured in DMEM/F12 with
10% fetal bovine serum (FBS). The isolated UC-derived MSCs were confirmed negative for
CD34 and positive for SSEA-4, CD73, CD90, and CD105.(25–27)
Palatal Periosteum MSC Harvest
Following IRB approval, PP MSCs were harvested from children undergoing cleft palate
repair using an explant technique as previously described. (11, 23) Four mm2 punch biopsies
were cut into small explants, and cultured in DMEM/F12 with 10% FBS. Surface markers
utilized for identification of MSC origin were similar to UC MSCs.(23, 25)
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To test for MSC surface markers, UC and PP MSC were analyzed by flow cytometry.(23)
Passage 1 cells were resuspended in cold blocking buffer (0.5% BSA, 0.01% Na azide in
PBS). Cells were treated with conjugated primary antibody for 20 mn on ice, washed with
cold PBS, fixed in 1% paraformaldehyde, and analyzed in a Beckman-Coulter (Dako,
Carpinteria, CA, USA) CyAn ADP using the Summit 4.3 software.
Osteoinduction
Passage 2 or 3 MSCs were seeded onto regular tissue culture plates (2-D) or PLGA scaffolds
at a density of 4 × 104 cells/cm2. Cells were then differentiated in α-MEM medium
supplemented with 10% FBS, 2mM glutamine, 0.1μM dexamethasone, 50 μM ascorbic acid,
10mM β-glycerophosphate, with media changes every 3 days. Cultures were assayed at days
1, 3, 7, 14 and 21 for cell viability, proliferation and osteogenic differentiation.
Cell proliferation
DNA quantification was used to evaluate cell proliferation. At the different time points, cells
were lysed in 10 mM Tris/HCl pH 8.0, 1 mM EDTA, 1% SDS and digested overnight at
55°C with 0.5 mg/ml proteinase K; enzyme was inactivated for 5 minutes at 95°C. The
DNA content of the samples was quantitated using the Quant-iT dsDNA BR Assay
(Invitrogen, Grand Island, NY, USA).
Cell Viability
To evaluate cell viability, cultures were washed in PBS and stained with green-fluorescent
calcein-AM and red-fluorescent ethidium homodimer-1, using the LIVE/DEAD® Viability/
Cytotoxicity assay (Invitrogen, Grand Island, NY, USA). Fluorescence staining was
visualized by fluorescence microcopy using a Nikon Eclipse Ti-S inverted microscope.
Alizarin Red S staining
To demonstrate the presence of insoluble calcium deposition, the osteoinduced cells were
fixed in 10% buffered formalin for 30 minutes and rinsed with distilled water. Cells were
stained with 2% Alizarin Red S solution at pH 4.2 for 10 minutes with gentle agitation. Cells
were then washed with distilled water to remove excess dye, followed by tap water. The
Alizarin Red S staining was analyzed under light microscopy using a Nikon Eclipse Ti-S
inverted microscope.
Alizarin Red quantification
For quantification of staining, Alizarin Red was extracted with 10% (v/v) acetic acid for 30
minutes at room temperature with shaking. After incubation, the cell monolayer with acetic
acid was transferred to a 1.5-mL microcentrifuge tube and vortexed for 30 sec. The solution
was then overlaid with mineral oil, heated at 85°C for 10 min, and transferred to ice for 5
min. Samples were then centrifuged at 20,000g for 15 min and the supernatant was mixed
with 10% (v/v) ammonium hydroxide (5:2) to neutralize the acid (final pH= 4.1–4.5).
Samples were read in triplicate at 405 nm.
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To analyze expression of genes involved in MSC osteogenic differentiation, the total cellular
RNA was isolated using the RNeasy total RNA extractionkit from Qiagen (Gaithersburg,
MD, USA). Real-time fluorescent quantitative PCR was performed by using an ABI PRISM
7700 (Applied Biosystems, Grand Island, NY, USA) using specific primers sequence for the
listed genes (Table 1). The ribosomal 18S RNA was used as an internal standard and the
2−ΔΔCT quantification method was used for data analysis.
Statistical analysis
Experiments were run in duplicate using at least four different cell lines to account for
individual variations. Values are reported as mean ± standard error of the mean of four
independent experiments. Statistical analyses were performed using GraphPad Prism 5®. A
two-way analysis of variance (ANOVA) test was used to determine significant differences
between groups. Comparison between means was determined using the Bonferroni post-hoc
test using a confidence level of 0.05.
Results
Scaffold diameter and porosity
PLGA polymer was successfully electrospun into homogenous scaffolds (Figure 2). Using
electron microscopy, mats were noted to contain a mixture of nano and micro fibers with
diameters ranging from 0.6 to 2.1 μm. Pore size distribution was homogenous, and
predominantly distributed between 0–6 μm.
Characterization of MSCs
Both populations of stem cells were negative for CD34 and demonstrated appropriate
surface markers for MSCs by flow cytometry (Figure 3). PP MSCs demonstrated
significantly lower levels of SSEA-4 and CD90, as previously reported,(23) and may be an
indication of greater pre-commitment of the periosteal-derived stem cells.
Proliferation and viability of MSCs on 2D and MNF surfaces
UC MSCs demonstrated an earlier increase in proliferation (day 3) for the PLGA condition
vs. the 2D culture (day 7). From day 3 onward, the PLGA NMF condition demonstrated
greater viability than the 2D condition (Figure 4). Declining cell proliferation was noted by
day 14 for PLGA conditions. Cell viability was maintained throughout the 14-day
experiments in both 2D and PLGA conditions.
Proliferation of PP MSCs increased by day 7 in 2D cultures and day 3 for PLGA; higher
proliferation rates were noted compared to UC MSCs. Unlike UC MSCs, PP MSC
proliferation started to decline at day 14 for both 2D and PLGA conditions. Direct
comparison of proliferation between UC and PP MSCs, suggests that PP proliferation is
higher in 2D cultures compared to UC at days 3 and 7 (Table 2). PLGA scaffold-induced
proliferation was similar for both PP and UC cells. Viability was lower for PP than UC
MSCs in all conditions. There seemed to be a correlation between earlier cell proliferation
and earlier decrease in viability.
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Calcium deposition during differentiation of MSCs
All osteoinduced conditions for both PP and UC MSCs demonstrated the presence of
calcium deposition (Figure 5). In UC MSCs, calcium deposition was first detected at day 7
and increased until day 14 for all conditions. Calcium deposition was higher for all NMF
scaffold than for 2D conditions. In PP MSC osteoinduction, calcium deposition was initially
detected at day 7, and increased until day 14 for 2D conditions, but not for PLGA-supported
conditions. Calcium deposition remained higher in 2D cultures than NMF scaffolds for days
14. PP MSCs demonstrated greater calcium deposition at days 14 than did UC MSCs. UC
MSC differentiation however demonstrated higher calcium deposition on NMFs than PP
(Table 2).
Analysis of gene expression during MSC differentiation
In UC MSCs, bone morphogenic protein-2 (BMP2) expression increased over time until day
14 for 2D cultures. PLGA-supported cultures demonstrated similar increased expression
until day 14 (Figure 6, Table 3). Alkaline phosphatase (ALP) mRNA increased over time in
all three conditions. Although not significant, there was a higher expression at day 3 in 2D
cultures compared to the NMF-supported cultures.
In PP MSC osteoinduction, BMP2 mRNA increased in 2D cultures until day 14. PP MSCs
differentiated on PLGA demonstrated a minor increase in BMP2 expression until day 14,
similar to UC-derived MSCs.
ALP mRNA mirrored BMP2 expression, demonstrating an increase over time in 2D
cultures. No increase was noted in PLGA-supported conditions. Osteocalcin (OTC) mRNA
increased by day 7 and continued until day 14 for cells seeded on 2D surfaces. An increase
was also detected for PLGA by day 14. Levels of OTC expression increased by day 14 in
PLGA conditions and were comparable to 2D levels. Osteopontin (OPN) mRNA expression
in PP MSCs increased at day 14 on 2D surfaces (Figure 7, Table 3).
Discussion
Strategies focused on tissue-engineered bone constitute a promising approach to overcome
current limitations in the surgical repair of craniofacial bone defects (limited graft supply
and the need for a secondary surgical site with attendant morbidities). In this study, we have
demonstrated that Stryker® resorbable Delta System™ can be electrospun reliably into a
combination of nanofibers and microfibers that mimic the ECM. These NMF scaffolds
provide a 3D surface for umbilical cord and palate periosteum MSC attachment,
proliferation, and osteoinduction.
In comparing MSCs from the two sources, we have noted that UC and PP MSCs possess
comparable surface markers (confirming their mesenchymal identity), with the exception of
CD90 and SSEA-4.(23) CD90 levels were lower in PP MSCs; because lower expression of
CD90 is an indication of a more differentiated state along a continuum of osteogenic
lineage, this is likely an indication that PP MSCs have a greater initial commitment to an
osteogenic lineage.(28, 29) Clinically, this appears logical because the role of periosteal
MSCs is to provide a source of bone healing following injury.(30) The higher percentage of
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UC MSCs with the surface marker SSEA-4, previously thought to be limited to embryonic
stem cells,(31) but more recently demonstrated on MSCs,(27, 32) is likely an indication that
UC MSCs are more primitive than those from the periosteum, and hence less committed to
an osteogenic lineage.
While both UC and PP MSCs were successfully osteoinduced, there was a qualitative
increase in osteogenic specific gene expression (in particular, BMP2) and calcium
deposition in UC MCSs. This increase was not detected in osteoinduced PP MSCs, which
conversely appeared to demonstrate improved differentiation on 2D surfaces. Stem cells that
possess characteristics of later stage osteogenic differentiation (e.g. PP MSCs) appear to die
in a few days under standard tissue culture conditions, in comparison to cultures of cells at
an earlier differentiation stage (consistent with the UC MSCs).(33) In our study, the
correlation between earlier differentiation and a shorter time period of viability for PP MSCs
when compared to UC MSCs supports this hypothesis.(33) Decrease in viability is even more
pronounced in nanofiber-supported conditions, correlating with an accelerated
differentiation into the osteogenic lineage with earlier appearance of late stage markers for
PP MSCs under these conditions. Our tentative conclusion is that NMF scaffolds induce
earlier differentiation in both sets of MSCs. Because the PP MSCs are already further along
in the osteogenic continuum, they complete this differentiation process sooner, and hence
lose viability sooner.
BMP2 and ALP are considered early markers in bone differentiation,(34) while OTC is an
indication of a more mature osteoblastic phenotype and terminal differentiation.(35)BMP2 is
involved in bone differentiation and regulates transcription of other osteogenic genes, in
particular, increasing the expression of both ALP and OTC. BMP2 mRNA increased as
early as day 3 for both UC and PP MSCs, followed by an increase in ALP, OTC, with
calcium deposition in the extracellular matrix, all of which is consistent with what is known
about BMP2 function.(34,35)
Osteogenic differentiation of PP MSCs starts earlier than in UC MSCs, with 2D cultures
showing higher BMP2 and higher calcium deposition by day 7. This is explained by the fact
that PP MSCs are already preconditioned toward an osteogenic lineage; earlier
differentiation capacity is supported by a lower CD90 surface marker distribution in PP
MSCs described earlier. While PP MSC differentiation is poorer on PLGA NMFconditions,
fiber scaffolds increased UC MSC differentiation to levels comparable to PP MSCs in 2D
conditions. MSC differentiation on PLGA-supported conditions begins earlier than 2D
conditions with demonstration of higher levels of BMP2 and calcium deposition.
Another protein marker of osteogenesis is OPN, which is produced by pre-osteoblasts,
mature osteoblasts, and osteocytes.(33) We detected an increase over time in OPN for PP
MSCs starting by day 7; however, no increase for UC MSCs was detected. Higher OPN
expression at day 14 in PP MSCs may also support the hypothesis of an earlier
differentiation capacity in PP MSCs.
OTC and OPN mRNA and protein are expressed by only limited subsets of osteoblasts,
depending on their maturational state and the microenvironment in which they reside.(33)
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Given this fact, the variations we noted in OPN and OTC expression levels may be
accounted for because the MSCs from both sources are not in synchronized cultures; they
exist as a mix of osteoblasts in various states of differentiation. In addition, the NMF may
generate microenvironments that further influence the generation of OTC and OPN. This
could be related to NMF degradation patterns, which we are currently studying.
In order to lay the foundation for pre-clinical studies to test UC MSC-bone forming capacity
in vivo, we have developed an autologous treatment algorithm in a juvenile swine model.
Swine umbilical cords are harvested at birth using an explant technique similar to that
performed in humans. The swine are identified, weaned at 3 weeks of age, acclimated for
two weeks at the North Carolina School of Veterinary Medicine large animal facility, then
undergo survival surgery. A critical sized maxillary defect is created, and treated with
autologous UC MSCs on the PLGA scaffolds utilized in this study. Our initial data suggests
that we are able to successfully generate bone within this defect.
In conclusion, both UC and PP MSCs attach, proliferate, and undergo osteogenic
differentiation on Stryker® resorbable Delta System™ NMFs. The PLGA NMFs appear to
have a greater trophic effect on the more primitive, less osteogenically committed, UC
MSCs. Because NMF scaffolds allow earlier osteogenesis with matrix deposition, this may
allow earlier implantation of tissue engineered constructs with potentially shorter times for
healing of bone defects. The added benefit is that the UC is a discarded tissue, readily
available at birth, simultaneous to the diagnosis of the craniofacial bone defect, and requires
no secondary procedure for harvest.
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Electrospinning apparatus. The electrospinning apparatus consists of a syringe attached to a
pump, which directs a viscous polymer across a voltage potential toward a collecting plate.
When the voltage potential overcomes the surface tension of the viscous polymer, the
polymer jet is directed toward the collecting plate where the fibers dry. Fiber diameters and
porosities (related to the density of the fiber mat) are controlled by polymer choice and
viscosity, diameter of the syringe needle, voltage potential, and distance to the collecting
plate.
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Nanomicrofiber (NMF) characterization. Poly-co-glycolytic acid (PLGA) fibers were
electrospun using standard techniques. Scanning electron micrographs (SEM) of these NMF
mats were obtained. Representative micrographs suggest that PLGA fibers and are a mixture
of fiber diameters (A). PLGA fiber diameters and porosities were measured by SEM; fibers
ranged from 0.6 to 2.1 μm in diameter (B) and pore sizes are within a 0 to 6 μm range (C).
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Mesenchymal stem cell (MSC) surface markers. Standard markers were determined for
MSCs harvested from Umbilical Cord (UC) (n = 6) and Palate Periosteum (PP) (n = 5)
sources using flow cytometry. All cells were negative for CD 34, a hematopoietic stem cell
marker, and positive for SSEA-4 (a primitive cell surface marker), CD 73, CD 90, and CD
105. Data are reported as the mean percentage of positive cells ± standard error of the mean.
Statistical analysis was performed using a double tailed, pair wise t-test. SSEA-4 (P ≤ 0.001;
***) and CD 90 (P ≤ 0.0001; ****) were statistically higher in UC MSCs.
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Mesenchymal Stem cells (MSC) proliferation and viability. Cell proliferation and viability
in Umbilical Cord (UC) and Palate periosteum (PP) MSCs (n = 4) seeded onto 2D surfaces
and PLGA fibers were assessed at days 1, 3, 7, 14, and 21 post-differentiation. Cell
proliferation was measured by DNA quantification for UC (A) and PP (B). Data were
reported as the mean total DNA in μg ± standard error of the mean. Statistical significance
was designated as P < 0.05 (*); no statistically significant differences were noted between
the conditions. Viability was qualitatively measured by Calcein AM staining; representative
pictures for UC (C) and PP (D) are shown. PLGA scaffolds supported proliferation sooner
and to a greater degree in MSCs from both sources.
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Calcium deposition measured by Alizarin Red staining. Umbilical cord (UC)- and palate
periosteum (PP)-mesenchymal stem cells (MSC) (n=3) were osteoinduced on 2D and PLGA
scaffolds; alizarin red staining for calcium deposition was assessed at days 1, 3, 7, and 14.
Calcium deposition was noted sooner (by day 7; A and C) and more sustained (at day 14) in
UC MSCs on PLGA scaffolds (p < 0.0001; ****). Calcium deposition was more
pronounced in PP-MSCs on PLGA scaffolds on days 3 and 7, but greater on 2D surfaces by
day 14 (B and D; without statistical significance). Statistical significance is reported as P ≥
0.05 (ns), P < 0.05 (*), P ≤ 0.01 (**), P ≤ 0.001 (***), P ≤ 0.0001 (****).
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Early markers of osteoinduction. Following osteoinduction of both umbilical cord (UC)- and
palate periosteum (PP-derived MSCs (n=5), mRNA for bone morphogenetic protein 2
(BMP2) (A, B) and alkaline phosphatase (ALP) (C, D) were assessed using RT-PCR. Fold-
increase in mRNA is recorded on the y-axis. BMP2 mRNA levels were higher in PLGA for
UC-MSCs at all time points (A), with statistical significance at day 14 (p ≤ .0001; ****)
while no difference was noted for ALP. For PP-MSCs, both BMP2 and ALP were higher in
2D surfaces (B, D). Data were reported as the 2−ΔΔCT mean ± standard error of the mean.
Statistical significance is reported as P ≥ 0.05 (ns), P < 0.05 (*), P ≤ 0.01 (**), P ≤ 0.001
(***), P ≤ 0.0001 (****).
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Late markers of osteoinduction. Following osteoinduction of both UC and PP-MSCs (n=5),
mRNA for OTC (A, B) and OPN (C, D) was assessed using RT-PCR. Fold-increase in
mRNA is recorded on the y-axis. OTC and OPN mRNA levels were similar in 2D and
PLGA for UC (A, C) through day 14. For PP-MSCs OTC and OPN levels are higher in 2D
than PLGA (B, D). Data were reported as the 2−ΔΔCT mean ± standard error of the mean.
Statistical significance is reported as P ≥ 0.05 (ns), P < 0.05 (*), P ≤ 0.01 (**), P ≤ 0.001
(***), P ≤ 0.0001 (****).
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